1630

U.s. der the Paperwork Reduction Act of 1995, no persons are required to respond to		U.S. Patent and Trademark	PTO/SB/21 (04-04) for use through 07/31/2006. OMB 0651-0031 Office; U.S. DEPARTMENT OF COMMERCE to unless it displays a valid OMB control number.	CLA
		Application Number	09/914,451-Conf. #4167	
TRANSMITTAL FORM		Filing Date	December 20, 2001	
		First Named Inventor	Jesper Z. HAEGGSTROM	
(to be used for all correspondence after initial filing)		Art Unit	1634	
		Examiner Name	D. B. Johannsen	
Total Number of Pages in This Submission	3	Attorney Docket Number	PVZ-006US	

	<u> </u>			
ENCLOSURES (Check all that apply)				
X Fee Transr	nittal Form	Drawing(s)	After Allowance communication to Technology Center (TC)	
Fee /	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences	
X Reply		Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	Final	Petition to Convert to a Provisional Application	Proprietary Information	
Affida	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter	
X Extension of Time Request		Terminal Disclaimer	Other Enclosure(s) (please Identify below):	
Express Abandonment Request		Request for Refund	Copy of Notice To Comply Return receipt postcard	
Information Disclosure Statement		CD, Number of CD(s)		
	opy of Priority			
Document(s) to Missing Parts/	Remarks		
	Application			
	onse to Missing Parts			
L unde	r 37 CFR 1.52 or 1.53			
	SIGNATI	JRE OF APPLICANT, ATTORNEY, OR	AGENT	
Firm or Individual name	LAHIVE & COCKFIELD, LLP Elizabeth A. Hanley - 33,505			
Signature	(944)			
Date	December 79, 2004			

, ,		al Ani. 140 Amandus		6. Postal Service as Express Mail, Airbill Commissioner for Patents, P.O. Box
Dated: December 🎾 , 2004	Signature: _	(104	\rightarrow	(Elizabeth A. Hanley)

PTO/SB/17 (12-04)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Effective on 12/08/2004. 09/914451-Conf. #4167 Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). **Application Number** FEE TRANSMITTAL December 20, 2001 Filing Date Jesper Z. HAEGGSTROM First Named Inventor For FY 2005 **Examiner Name** D. B. Johannsen Applicant claims small entity status. See 37 CFR 1.27 1634 Art Unit PVZ-006US TOTAL AMOUNT OF PAYMENT 1,080.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Credit Card None Other (please identify): Money Order x Deposit Account 12-0080 Lahive & Cockfield, LLP Deposit Account Number:_ _ Deposit Account Name:_ For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) x Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or any underpayment of x Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Small Entity Small Entity Small Entity Application Type** Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 500 200 150 250 100 Design 200 100 100 50 130 65 Plant 200 100 300 150 160 80 Reissue 300 150 500 250 600 300 **Provisional** 200 100 0 0 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) Fee Description Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent 50 25 Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent 200 100 Multiple dependent claims 360 180 **Total Claims Multiple Dependent Claims** Extra Claims Fee (\$) Fee Paid (\$) Fee (\$) Fee (\$) Extra Claims Indep. Claims 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Extra Sheets Number of each additional 50 or fraction thereof Fee Paid (\$) _____ (round up to a whole number) x 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other: 2255 Extension for response within fifth month 1,080.00 SUBMITTED BY Registration No. Signature 33.505 Telephone (617) 227-7400 (Attorney/Agent) Name (Print/Type) Elizabeth A. Hanley Date December

I hereby certify that this correspondenc	e is being deposi	ited with the U.S. Postal Service tents, P.Q. Box 1450, Alexandria	as Express Mail, Airbill No. EL 981 582 317
US, in an envelope addressed to: Corr	missioner for Pa		a, VA 22313-1450, on the date shown below.
Dated: December 🎾 , 2004	Signature: _	(NN)	a, VA 22313-1450, on the date shown below. (Elizabeth A. Hanley)

OLE 2 8 2004 VIEW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EL 981582317 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Alexandria, VA 22515-1450, on the t

Signature:

(Elizabeth A. Hanley, Esq.)

Docket No.: PVZ-006US

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jesper Z. Haeggstrom *et al.*

Application No.: 09/914,451 Confirmation No.: 4167

Filed: December 20, 2001 Art Unit: 1634

For: DRUG DESIGN BASED ON THE Examiner: D. B. Johannsen

STRUCTURE OF LTA₄ HYDROLASE

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 1, 2004. The U.S. Patent and Trademark Office has taken the position that this application fails to comply with the requirements of 37 C.F.R. § 1.821-1.825. In particular, the Examiner notes, "the Sequence listing is incomplete (See, e.g., the numerous polypeptide variants of Tables 5-7, as well as those recited in the pending claims)."

Applicants respectfully submit that the Sequence Listing does comply with the requirements of 37 CFR § 1.821-1.825 for the following reasons.

The requirements of 37 C.F.R. § 1.821-1.825 state that "Nucleotide and/or amino acid sequences as used in §§ 1.821 through 1.825 are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. []

Application No.: 09/914,451 Docket No.: PVZ-006US

Sequences with fewer than four specifically defined nucleotides or amino acids are specifically excluded from this section." (See 37 CFR § 1.821(a).)

The variants of the present application, *e.g.*, Tables 5-7, are not sequences of four or more amino acids. These tables show single amino acids which can be mutated on the LTA₄ hydrolase. Specifically, the amino acids are given a single letter code corresponding to the LTA₄ numbering scheme and then list the possible mutations of the present invention. For example, Q134G/A/V/L/I/S/T/D/E/N/R/H/K/P/C/M/F/Y/W indicates that the glutamine (Q) at residue 134, using the LTA₄ numbering scheme, may be modified to a glycine (G), an alanine (A), a valine (V), a leucine (L), and so forth. (See page 17, lines 18 through 23.) Therefore, there is no requirement to label these single amino acids with sequence identifiers. Accordingly, Applicants respectfully request that the Examiner reconsider and withdraw this Notice.

SUMMARY

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

A request for a five-month extension of time is being filed concurrently herewith. Applicants believe no additional fee is due with this Response. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. PVZ-006US from which the undersigned is authorized to draw.

Dated: 17 12/07

Respectfully submitted,

Elizabeth A. Harlley

Registration No. 33,505

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney For Applicants

Application No.: 09/914,451

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUMBER 10 SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. The Sequence Listing is incomplete (i.e., does not include all sequences).
Ap	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For Pat	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY